Under the partnership, the Secaucus-based company becomes the first national laboratory to implement these services across a range of areas.

Quest Diagnostics logged a -1.0% change during today's afternoon session, and is now trading at a price of $166.27 per share.

Public health labs have handled most testing thus far for the Texas and New Mexico outbreaks, but commercial labs are beginning to bring molecular measles assays online.

Baird raised the firm’s price target on Quest Diagnostics (DGX) to $191 from $190 and keeps an Outperform rating on the shares. The firm ...

In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on Quest Diagnostics (DGX – Research Report). The ...

The board of Quest Diagnostics Incorporated ( NYSE:DGX ) has announced that it will be paying its dividend of $0.80 ...

Quest Diagnostics, GE Healthcare and Synchron were among the medtech firms that used Nvidia’s GTC 2025 conference to share ...

Proponents herald the practice as a free-market approach to providing medical care, while critics say it could widen health ...

This was the stock's second consecutive day of losses.

Despite Monday’s market uptick, broader indices remain lower year-to-date as investors grapple with uncertainties surrounding ...

Quest Diagnostics adjusts Q1 revenue & EPS outlook due to weather impact, projects 4-5% CAGR revenue growth beyond 2025. Read ...

Quest Diagnostics announced it is teaming up with Google Cloud to develop artificial intelligence programs that can ...